These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
276 related articles for article (PubMed ID: 8684529)
1. Gadodiamide in renal transplant patients: effects on renal function and usefulness as a glomerular filtration rate marker. Berg KJ; Lundby B; Reinton V; Nordal KP; Rootwelt K; Smith HJ Nephron; 1996; 72(2):212-7. PubMed ID: 8684529 [TBL] [Abstract][Full Text] [Related]
2. Comparison of nephrotoxicity between two gadolinium-contrasts, gadodiamide and gadopentetate in patients with mildly diminished renal failure. Naito S; Tazaki H; Okamoto T; Takeuchi K; Kan S; Takeuchi Y; Kamata K J Toxicol Sci; 2017; 42(3):379-384. PubMed ID: 28496044 [TBL] [Abstract][Full Text] [Related]
3. Accurate, fast, and convenient measurement of glomerular filtration rate in potential renal transplant donors. Rabito C; Halpern EF; Scott J; Tolkoff-Rubin N Transplantation; 2010 Sep; 90(5):510-7. PubMed ID: 20595931 [TBL] [Abstract][Full Text] [Related]
4. Elimination of gadolinium-DTPA by peritoneal dialysis. Dörsam J; Knopp MV; Schad L; Piesche S; Carl S; Oesingmann N Nephrol Dial Transplant; 1995; 10(7):1228-30. PubMed ID: 7478129 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of Gd-DTPA in patients with chronic renal failure. Schuhmann-Giampieri G; Krestin G Invest Radiol; 1991 Nov; 26(11):975-9. PubMed ID: 1743921 [TBL] [Abstract][Full Text] [Related]
6. In vivo stability and excretion of gadodiamide (GdDTPA-BMA), a hydrophilic gadolinium complex used as a contrast enhancing agent for magnetic resonance imaging. Normann PT; Hals PA Eur J Drug Metab Pharmacokinet; 1995; 20(4):307-13. PubMed ID: 8983938 [TBL] [Abstract][Full Text] [Related]
7. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. Harpur ES; Worah D; Hals PA; Holtz E; Furuhama K; Nomura H Invest Radiol; 1993 Mar; 28 Suppl 1():S28-43. PubMed ID: 8486501 [TBL] [Abstract][Full Text] [Related]
8. Renal tolerance of gadolinium-DTPA/dimeglumine in patients with chronic renal failure. Haustein J; Niendorf HP; Krestin G; Louton T; Schuhmann-Giampieri G; Clauss W; Junge W Invest Radiol; 1992 Feb; 27(2):153-6. PubMed ID: 1601607 [TBL] [Abstract][Full Text] [Related]
9. Comparison of simultaneous renal clearances of true endogenous creatinine and subcutaneously administered iothalamate in man. Pollock C; Gyory AZ; Hawkins T; Ross M; Ibels L Am J Nephrol; 1995; 15(4):277-82. PubMed ID: 7573183 [TBL] [Abstract][Full Text] [Related]
10. Iodixanol 320 results in better renal tolerance and radiodensity than do gadolinium-based contrast media: arteriography in ischemic porcine kidneys. Elmståhl B; Nyman U; Leander P; Golman K; Chai CM; Grant D; Doughty R; Pehrson R; Björk J; Almén T Radiology; 2008 Apr; 247(1):88-97. PubMed ID: 18292474 [TBL] [Abstract][Full Text] [Related]
11. Determination of glomerular filtration rate using technetium-99m-DTPA with differing degrees of renal function. Morton KA; Pisani DE; Whiting JH; Cheung AK; Arias JM; Valdivia S J Nucl Med Technol; 1997 Jun; 25(2):110-4. PubMed ID: 9239614 [TBL] [Abstract][Full Text] [Related]
12. Dialyzability of gadodiamide in hemodialysis patients. Saitoh T; Hayasaka K; Tanaka Y; Kuno T; Nagura Y Radiat Med; 2006 Jul; 24(6):445-51. PubMed ID: 16958426 [TBL] [Abstract][Full Text] [Related]
13. Gadodiamide injection. First human experience with the nonionic magnetic resonance imaging enhancement agent. Van Wagoner M; Worah D Invest Radiol; 1993 Mar; 28 Suppl 1():S44-8. PubMed ID: 8486503 [TBL] [Abstract][Full Text] [Related]
14. Diagnosis of renal artery stenosis: feasibility of combining MR angiography, MR renography, and gadopentetate-based measurements of glomerular filtration rate. Ros PR; Gauger J; Stoupis C; Burton SS; Mao J; Wilcox C; Rosenberg EB; Briggs RW AJR Am J Roentgenol; 1995 Dec; 165(6):1447-51. PubMed ID: 7484583 [TBL] [Abstract][Full Text] [Related]
15. Performance of methods to assess kidney function in a predominantly overweight sample of patients with liver disease. Hudson JQ; Owens HM; Fleckenstein JF; Loveless VS; Krauss AG; Hak LJ Ren Fail; 2013; 35(2):249-56. PubMed ID: 23176438 [TBL] [Abstract][Full Text] [Related]
16. A double blind study to evaluate the tolerability of gadodiamide injection and its effect on renal function in patients undergoing cerebral magnetic resonance imaging. Lundby B; Berg KJ; Lien HH; Aamdal S Br J Radiol; 1993 Oct; 66(790):871-6. PubMed ID: 8220968 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics in rats, dogs and monkeys of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging. Schuhmann-Giampieri G; Frenzel T; Schmitt-Willich H Arzneimittelforschung; 1993 Aug; 43(8):927-31. PubMed ID: 8216456 [TBL] [Abstract][Full Text] [Related]
18. 125I-iothalamate and creatinine clearances in patients with chronic renal diseases. Tessitore N; Lo Schiavo C; Corgnati A; Previato G; Valvo E; Lupo A; Chiaramonte S; Messa P; D'Angelo A; Zatti M; Maschio G Nephron; 1979; 24(1):41-5. PubMed ID: 492407 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Joffe P; Thomsen HS; Meusel M Acad Radiol; 1998 Jul; 5(7):491-502. PubMed ID: 9653466 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and stability of caldiamide sodium in rats. Okazaki O; Kurata T; Yoshioka N; Hakusui H Arzneimittelforschung; 1996 Jan; 46(1):79-83. PubMed ID: 8821523 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]